Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Eli Lilly & Co., consolidated balance sheet: assets

US$ in thousands

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Cash and cash equivalents 2,818,600 2,067,000 3,818,500 3,657,100 2,337,500
Short-term investments 109,100 144,800 90,100 24,200 101,000
Accounts receivable, net of allowances 9,090,500 6,896,000 6,672,800 5,875,300 4,547,300
Other receivables 2,245,700 1,662,900 1,454,400 1,053,700 994,200
Inventories 5,772,800 4,309,700 3,886,000 3,980,300 3,190,700
Prepaid expenses 5,540,800 2,946,800
Other current assets 149,500 7,300 2,530,600 2,871,500 2,538,900
Current assets 25,727,000 18,034,500 18,452,400 17,462,100 13,709,600
Investments 3,052,200 2,901,800 3,212,600 2,966,800 1,962,400
Goodwill 4,939,700 4,073,000 3,892,000 3,766,500 3,679,400
Other intangibles, net 6,906,600 7,206,600 7,691,900 7,450,000 6,618,000
Deferred tax assets 5,477,300 2,792,900 2,489,300 2,830,400 2,572,600
Property and equipment, net 12,913,600 10,144,000 8,985,100 8,681,900 7,872,900
Other noncurrent assets 4,989,900 4,337,000 4,082,700 3,475,400 2,871,200
Noncurrent assets 38,279,300 31,455,300 30,353,600 29,171,000 25,576,500
Total assets 64,006,300 49,489,800 48,806,000 46,633,100 39,286,100

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Eli Lilly & Co. current assets decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Property and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Eli Lilly & Co. property and equipment, net increased from 2021 to 2022 and from 2022 to 2023.
Noncurrent assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Eli Lilly & Co. noncurrent assets increased from 2021 to 2022 and from 2022 to 2023.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Eli Lilly & Co. total assets increased from 2021 to 2022 and from 2022 to 2023.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Eli Lilly & Co. cash and cash equivalents decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.
Short-term investments Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. Eli Lilly & Co. short-term investments increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Accounts receivable, net of allowances Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Eli Lilly & Co. accounts receivable, net of allowances increased from 2021 to 2022 and from 2022 to 2023.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Eli Lilly & Co. inventories increased from 2021 to 2022 and from 2022 to 2023.